On March 21, 2018, Xiaoyan (Henry) Liu informed NovaBay Pharmaceuticals, Inc. that he will resign as a member of the company’s Board of Directors, with such resignation to be effective immediately. On March 21, 2018, effective upon the resignation of Mr. Henry Liu, the Board appointed Yanbin (Lawrence) Liu to fill the vacancy on the Board resulting from the resignation of Mr. Henry Liu. Mr. Lawrence Liu will take Mr. Henry Liu’s place as a Class III director to serve until the company’s Annual Meeting of Stockholders in 2019, subject to his prior death, resignation or removal from office as provided by law. Mr. Lawrence Liu is a non-independent member and will not serve on any committees of the Board. Mr. Lawrence Liu has served as the Joint Chief Operating Officer & Head of Direct Investment of OP Financial Investments Limited in Hong Kong since February 2015. Mr. Lawrence Liu is particularly experienced in cross-border direct investment. Mr. Lawrence Liu was the Investment Director of China-ASEAN Capital Advisory Co. Ltd. from 2014 to 2015. From 2011 to 2014, Mr. Lawrence Liu served as the Head of Project Finance & Syndication Department (EMEA Coverage) and from 2006 to 2011 as the Head of M&A and Structured Finance Department, Corporate Banking, both at the Bank of China Limited in London. From 2002 to 2006, Mr. Lawrence Liu served as the Key Account Manager, Corporate Banking at the Bank of China Limited in Beijing.